
Elraglusib Combo Improves Survival in First-Line mPDAC
The combination of elraglusib (9-ING-41), a potent small molecule inhibitor of GSK-3β, and gemcitabine and nab-paclitaxel (Abraxane) achieved statistical significance when used for the first-line treatment of metastatic pancreatic ductal adenocarcinoma ( …